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Objective: In this preliminary study we tested the effect of short-term carbohydrate supplementation on carbohydrate
oxidation and walking performance in peripheral arterial disease.
Methods: Eleven patients with peripheral arterial disease and intermittent claudication and 8 healthy control subjects
completed several weeks of baseline exercise testing, then were given supplementation for 3 days with a carbohydrate
solution and placebo. Maximal walking time was assessed with a graded treadmill test. Carbohydrate oxidation during a
submaximal phase of this test wasmeasured with indirect calorimetry. At the end of baseline testing a biopsy specimenwas
taken from the gastrocnemiusmuscle, and the active fraction of pyruvate dehydrogenase complex activity was determined.
Results: Carbohydrate supplementation resulted in a significant increase in body weight and carbohydrate oxidation
during exercise in patients with intermittent claudication and control subjects. Maximal walking time decreased by 3% in
control subjects, whereas it increased by 6% in patients with intermittent claudication (group  treatment interaction, P
< .05). There was a wide range of performance responses to carbohydrate supplementation among patients with
claudication (3%-37%). This effect was greater in poorer performers, and was negatively correlated (P < .05) with
muscle pyruvate dehydrogenase complex activity.
Conclusion: Preliminary data suggest that carbohydrate oxidation during exercise might contribute to exercise intolerance
in more dysfunctional patients with intermittent claudication and that carbohydrate supplementation might be an
effective therapeutic intervention in these patients. ( J Vasc Surg 2004;40:932-8.)Walking intolerance is a major problem for patients with
peripheral arterial disease and its classic symptom, intermittent
claudication. To a large extent this intolerance to exercise can
be explained by the degree of restriction of blood flow to the
active limbs, although in poorer performers this relationship
seems to be weakened.1,2 This latter observation is one of
several that suggest that factors in addition to blood flow
contribute to exercise intolerance in intermittent claudication,
particularly in less able patients,3 and in this respect attention
has been focused on the role of metabolic factors intrinsic to
skeletal muscle.4
Brass and Hiatt4 suggested that a metabolic myopathy
is acquired in patients with intermittent claudication, al-
though how it contributes to exercise intolerance is not
clear. One aspect of this “myopathy” might relate to the
mitochondrial oxidation of carbohydrate. Dahllof et al5
showed that a brief period of supplementation with a
glucose polymer increased exercise performance in 4 of 6
patients with claudication and that this effect was positively
related to the concomitant effect onmuscle glycogen levels.
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932Although the mechanism underpinning these effects is
unclear, it might be focused on the pyruvate dehydroge-
nase complex (PDC), given that its level of activation at rest
is sensitive to such dietary maneuvers6,7 and that its control
is central to the mitochondrial oxidation of carbohydrate.
Recently we isolated mitochondria from the calf muscle of
patients with claudication and showed that the rates of
mitochondrial oxidation of carbohydrate (PDC-depen-
dent) are positively correlated with walking performance
and increased with exercise training.8 In contrast, the rates
of mitochondrial oxidation of an esterified fatty acid
(palmitoyl-L-carnitine) are not correlated with perfor-
mance, and are unaltered by training.8 These data suggest
that differences in the mitochondrial oxidation of carbohy-
drate in resting muscle of patients with claudication, per-
haps linked to the activation status of PDC, might affect
exercise performance through either more rapid increase in
oxygen uptake at the onset of exercise or a more favorable
adenosine triphosphate–oxygen ratio for carbohydrate, as
opposed to fatty acid, oxidation.8,9 Whether changes in
carbohydrate oxidation can alter exercise performance in
claudication is not known.
To explore this further, in the present study we tested
the effect of carbohydrate oxidation on walking perfor-
mance in intermittent claudication by altering rates of
whole-body carbohydrate oxidation through dietary sup-
plementation with carbohydrate. This preliminary physio-
logic study was also designed to determine whether any
ergogenic effect was mediated by changes in the kinetics of
the oxygen uptake response during exercise and whether
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PDC in resting calf muscle before supplementation.
METHODS
Subjects. We examined 8 healthy control subjects (5
men, 3 women; age, 66 8 years), and 11 patients (8 men,
3 women; age, 63 8 years) with intermittent claudication
and peripheral arterial disease, according to clinical history,
duplex ultrasound scans, and resting ankle-brachial index
(ABI) less than 0.9. Exclusion criteria for patients with
claudication included diabetes mellitus, ischemic pain at
rest, hospitalization during the 6 months before the study,
or exercise performance limited by any symptom other than
intermittent claudication. During the study all patients
with claudication received prescribed medications, includ-
ing statins, and no subject received an experimental drug
immediately before or during the study. The study was
conducted in accordance with National Health and Medi-
cal Research Council guidelines, and was approved by the
research ethics committees of the participating institutions.
All subjects gave written informed consent before partici-
pation.
Experimental overview. All subjects reported to the
laboratory at approximately the same time of day once a
week for 9 weeks. Subjects performed a maximal incremen-
tal treadmill test once a week for the first 5 weeks, and in
week 6 a muscle biopsy specimen was taken from the calf.
One week later each subject performed a maximal treadmill
test after having been fed a carbohydrate supplement or
placebo for 3 days, and returned 2 weeks later and per-
formed a second treadmill test after having consumed the
other supplement for 3 days. Subjects were asked not to
alter their diet during the study, and they recorded their
diet during the placebo and carbohydrate phases. All sub-
jects were asked to consume the same meals during these
phases.
Dietary supplementation. Subjects consumed either a
high carbohydrate beverage (CHO) or an equal amount of
artificially sweetened water (placebo). Carbohydrate supple-
mentation consisted of Polycose glucose polymers (94% glu-
cose, 6% water, 3.8 cal/g; Abbott Laboratories), and 700 g
was dissolved in 6 L of water (11.7% glucose solution). Sub-
jects consumed 2 L per day, and distributed their consump-
tion over at least 3meals. The placebo drink consisted of 1.2 g
of sweetener (20% aspartame, 10%Acesulfame-K) dissolved in
6 L of water. Both supplements were colorless, with a mildly
sweet taste. Subjects and the experimenterwere blinded to the
order of presentation, and the order was counterbalanced by
another investigator. The subjects were unaware of the ex-
pected efficacy of either supplement.
Walking performance. Maximal walking time (walk-
ing performance) was assessed on a motorized treadmill set
at a speed of 3.2 km/h. During the initial 5 minutes of
exercise the grade was zero, and thereafter it was increased
3.5% every 3 minutes until exhaustion in the control sub-
jects or intolerable claudication pain in the patients.10
Vertical work was calculated using the subject’s weight,
treadmill speed, grade, and time spent on each grade.Pulmonary gas exchange. During all walking tests
the rate of oxygen uptake (VO2) and carbon dioxide pro-
duction (VCO2), respiratory exchange ratio, and respira-
tory minute ventilation (VE) were measured breath by
breath with an automated gas analysis system (CPX; Med-
ical Graphics Corp). Before each test the machine was
manually calibrated with gases of known concentration
prepared to the highest (alpha) standard. The pneumota-
chometer was calibrated manually with a 3-L syringe with
flow rates that simulated the range expected during exer-
cise. Peak data were calculated as the average of the peaks
attained during each test. Carbohydrate oxidation rates
during the final minute of the first stage of walking were
calculated from VO2 and respiratory exchange ratio data.
11
VO2 kinetics. Breath-by-breath VO2 responses at rest
and during the first 5 minutes of the maximal walking test
(0% grade) were interpolated to 1-second intervals. Data
from the 3 baseline tests were then time-aligned to the start
of walking, and were averaged to produce a single response.
VO2 responses measured during the single tests of each
supplement phase (CHO and placebo) were simply inter-
polated to 1-second intervals, and were time aligned to the
start of exercise. Phase II (fast component) kinetics of the
VO2 responses were then assessed with the following equa-
tion:VO2(t)VO2(a) b(1 e
[tTD/]), whereVO2(t)
is VO2 at time t, VO2(a) is resting baseline VO2, b is the
amplitude of the VO2 response from rest to steady state,
TD is the time delay from onset of exercise to initiation of
phase II, and  is the time constant. We excluded phase I of
the VO2 response, which does not represent muscle oxygen
consumption, from our equation with an approach that we
have described in more detail elsewhere.9 Curve fitting and
parameter estimation were made with weighted least-
squares nonlinear regression techniques and TableCurve
software.
ABI. During the familiarization phase, brachial sys-
tolic pressure was determined 3 times in both arms, with a
fully automated measuring device (Criticon). The arm with
the highest average pressure was used at all subsequent
visits. Systolic arterial pressure within the dorsalis pedis and
posterior tibial arteries at the ankles of both legs were
measured 3 times each at rest, with a continuous-wave
Doppler scanning probe and a manual sphygmomanome-
ter. In each leg the artery with the highest mean resting
systolic pressure was used at all subsequent visits. ABI was
calculated as the ratio of ankle systolic pressure to brachial
systolic pressure. At rest all sites weremeasured 3 times, and
the average value was used in calculations. Post-exercise
systolic pressure at the arm and both ankles was obtained 2,
4, and 8 minutes after finishing the treadmill test. In all
patients there was agreement between the leg with the
lowest resting ABI and the most severe pain experienced
during walking, and was termed the low ABI leg.
Muscle biochemistry. After 20 minutes of supine rest
a sample was taken from the medial gastrocnemius muscle
in the low ABI leg in 10 of 11 patients with claudication
and in a leg selected at random in the control subjects. After
administration of local anesthetic (lidocaine 1%) a small
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biopsy needle and immediately frozen in liquid nitrogen. A
total of 10 to 30 mg was chipped from each muscle sample
under liquid nitrogen and analyzed for the activity of the
active fraction of the pyruvate dehydrogenase complex
(PDCa).7,12
Statistical analysis. The first 2 maximal treadmill tests
were familiarization tests and were not included in the
analyses. For all variables measured during the next 3
baseline tests there was no significant main effect of time.
Consequently, each subject’s average response across weeks
3 to 5 was used to represent the baseline response. Two-
way analysis of variance with repeated measures and the
Tukey honestly significant difference (HSD) test were then
used to locate differences between phases. Relationships
between variables were assessed with Pearson product-
moment correlation coefficients. Results are expressed as
mean and SD, and P  .05 was considered significant.
RESULTS
Maximal exercise. Maximal walking times and peak
responses of physiologic variables under the 3 conditions
are shown in Table I. There was a significant interaction for
maximal walking time, such that carbohydrate supplemen-
tation increased performance in intermittent claudication
by approximately 6% and decreased performance in control
subjects by approximately 3%, compared with baseline or
placebo. Peak VO2 (mL/kg/min) was also significantly
reduced by carbohydrate supplementation in control sub-
jects, an effect that is only partly explained by the increase in
body weight (see below). In contrast, vertical work was not
significantly different in control subjects between baseline
(78.7  32.9 kJ), CHO (73.7  28.8 kJ), and placebo
(75.1 30.3 kJ), or in patients with intermittent claudica-
Table I. Maximal walking times and peak responses of ph





Peak oxygen uptake (ml/kg/min)
Control subjects 26.5
Patients 16.4
Peak minute ventilation (1/min)
Control subjects 77.6
Patients 58.4
Peak respiratory exchange ratio
Control subjects 1.16
Patients 1.10
Peak heart rate* (bpm)
Control subjects 161
Patients 124
*Significant difference between groups across all conditions
†Significantly different from baseline.
‡Significantly different from baseline and placebo.tion (n  8) between baseline (32.5  21.9 kJ), CHO(34.5  21.2), and placebo (32.1  21.6 kJ). Three
patients with claudication failed to complete the first stage,
performed no vertical work, and were thus not included in
the analysis. Peak respiratory exchange ratio was signifi-
cantly higher with CHO in both groups.
ABI. Resting ABI was not changed by supplementa-
tion in patients with intermittent claudication (baseline,
0.72 0.14; CHO, 0.70 0.12; placebo, 0.71 0.16) or
control subjects (baseline, 1.17  0.13; CHO, 1.16 
0.12; placebo, 1.19 0.15). ABI measured 2 minutes after
cessation of exercise (lowest ABI) also was not affected by
supplementation in patients with intermittent claudication
(baseline, 0.29  0.19; CHO, 0.29  0.17; placebo, 0.28
 0.20) and control subjects (baseline, 0.90 0.16; CHO,
0.94  0.16; placebo, 0.94  0.20).
Submaximal exercise. Physiologic responses mea-
sured during the last minute of the first stage of the walking
test (5 minutes) are shown in Table II. Respiratory ex-
change ratio was significantly higher in patients with inter-
mittent claudication and control subjects under CHO
compared with the remaining conditions, whereas VO2,
VE, and heart rate were not different across conditions. In
intermittent claudication the rates of carbohydrate oxida-
tion were significantly higher during CHO (8.1  3.6
mg/kg/min) compared with baseline (6.3  2.6 mg/kg/
min) or placebo (5.9  3.4 mg/kg/min). In control
subjects the rates of carbohydrate oxidation were signifi-
cantly higher during CHO (7.1  2.7 mg/kg/min) com-
pared with placebo (4.1  2.8 mg mg/kg/min), but not
baseline (5.7  2.8 mg/kg/min; P  .13). Neither total
amplitude of VO2 response (parameters a plus b from the
equation) nor time constant of the VO2 response were
different across conditions in patients with claudication and
ogic variables during baseline, carbohydrate
ittent claudication and control subjects
Carbohydrate
supplementation Placebo
1290 250† 1308 258
697 313‡ 661 329
25.0 4.0† 26.9 5.4
16.6 4.4 16.3 4.7
7 74.1 18.3 75.0 19.7
5 59.8 27.8 57.0 27.9
8 1.22  0.10‡ 1.17 0.09
6 1.15  0.13‡ 1.10 0.14
160 15 159 15












 27control subjects. Resting responses for these variables were
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conditions.
Body weight. For both control subjects and patients
with intermittent claudication, body weight was signifi-
cantly higher after CHO (control subjects, 73.9 13.5 kg;
patients, 83.2  17.7 kg) compared with baseline (control
subjects, 73.1  13.4 kg; patients, 82.3  17.8 kg) and
placebo (control subjects, 73.2 13.5 kg; patients, 82.5
17.4 kg).
Correlations. The effect of carbohydrate supplementa-
tion on walking performance, expressed as the difference
between baseline and CHO scores, was inversely related to
baseline walking performance in patients with intermittent
claudication (Fig 1). Analysis of this same relationship in the
absence of the 2 patients who responded most to CHO had
little effect on this correlation (r  0.62), which suggests
that this association is robust and clearly different from that
observed in control subjects. As seen in Fig 2, 6 of 11 patients
with claudication were considered to respond positively to
CHO, inasmuch as the ergogenic effect exceeded their indi-
vidual coefficients of variation (Cv) for walking performance
(meanCv, 6%) calculated from the 3 baseline tests; in contrast,
none of the control subjects responded positively to CHO
despite a low Cv (mean Cv, 3%). The difference in maximal
walking time betweenCHOandbaselinewas not significantly
correlated with the corresponding difference in rate of carbo-
hydrate oxidation during submaximal exercise for patients (r
 0.41) or control subjects (r  0.38). However, the
ergogenic effect of CHO in patients with claudication was
inversely related to the corresponding effect on the VO2 time
constant (Fig 3) and the single (baseline) estimate of skeletal
muscle PDCa activity (Fig 4). The strength of this latter
association was reduced only slightly (from r0.65 to r
 0.57) when the large responder with the lowest PDCa
Table II. Physiologic responses measured during last min
of oxygen use time constant () during baseline, carbohyd
intermittent claudication and control subjects
Baselin
Oxygen uptake (ml/kg/min)
Control subjects 10.6 1
Patients 10.3 1
* (s)
Control subjects 18.2 6
Patients 34.0 14
Minute ventilation
Control subjects 22.6 4
Patients 27.6 6
Respiratory exchange ratio
Control subjects 0.84 0.
Patients 0.86 0.
Heart rate (bpm)
Control subjects 90 12
Patients 85  18
*Significant difference between groups across all conditions.
†Significantly different from baseline and placebo.activity (0.2 mmol/min/kg) was excluded from the analysis.In patients with claudication larger reductions in the VO2
time constant were observed in persons with lower muscle
PDCa activity under CHO compared with baseline, such that
themagnitude of this reduction in the VO2 time constant was
negatively correlated with skeletal muscle PDCa activity in
patients with claudication (r  0.83; P  .05), but not in
control subjects (r0.19). In control subjects only, a larger
increase in body weight under CHO (relative to baseline) was
associatedwith a larger decline in performance under the same
condition (Fig 5).
DISCUSSION
The main findings of the present study were that in the
presence of increased rates of whole-body oxidation of
f first stage of walking test (5 minutes) and peak volume
upplementation, and placebo conditions in patients with
Carbohydrate
supplementation Placebo
10.3  1.6 10.8  1.8
10.0  1.1 9.7  1.0
22.4  6.4 21.9  8.7
36.2  13.4 33.3  12.5
22.6  3.0 21.4  4.3
28.6  7.2 25.5  4.2
0.87 0.07† 0.82  0.07
0.94 0.09† 0.84  0.06
88  12 89  12
95  22 87  22
Fig 1. Relationship between relative change in walking perfor-
mance with carbohydrate supplementation from baseline, and
baseline walking performance in patients with intermittent claudi-










05carbohydrate (1) carbohydrate supplementation exerted a
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intermittent claudication (increase by 37 seconds) com-
pared with healthy control subjects (decrease by 45 sec-
onds), and (2) the ergogenic effect in patients was inversely
related to the extent of functional impairment and skeletal
muscle PDCa activity at baseline. These preliminary data
raise the possibility that muscle carbohydrate oxidation
exerts an important effect on walking performance in pa-
tients with claudication, and suggest that a brief period of
supplementation with carbohydrate might be of therapeu-
tic value in some patients.
We did not measure metabolic changes within skeletal
muscle (eg, glycogen, PDCa) in response to the supple-
ments. Doing so was considered too invasive in these older
persons. However, a carbohydrate supplementation proto-
col similar to that used in the present study increased
muscle glycogen in 4 of 6 patients with claudication stud-
ied.5 Moreover, the increase in respiratory exchange ratio
Fig 2. Coefficient of variation of walking performance (shown as
half an error bar) for each control subject (A) and patient with
intermittent claudication (B) and superimposed on the relation-
ship between the effect of carbohydrate supplementation on per-
formance and baseline walking performance.and carbohydrate oxidation at rest and during submaximalexercise (Table II) is a consistent response to short-term
carbohydrate-enriched diets that also increase muscle gly-
cogen content and PDCa activity.6,7 Therefore it is likely
that similar metabolic changes in skeletal muscle occurred
in response to carbohydrate supplementation in the present
study.
A new finding was the significant difference in the perfor-
mance response to carbohydrate supplementation in patients
with intermittent claudication and control subjects. Although
the average improvement in claudication was small, it is im-
portant to note that there was a considerable range of re-
sponses in this group (Fig 1). If a positive response to CHO is
defined on the basis of the relative effect exceeding the indi-
Fig 3. Relationship between change in walking performance with
carbohydrate supplementation from baseline, and corresponding
change in time constant for oxygen uptake () in patients with
intermittent claudication (IC; open symbols) and control subjects
(closed symbols).
Fig 4. Relationship between relative change in walking perfor-
mance with carbohydrate supplementation from baseline, and
skeletal muscle pyruvate dehydrogenase complex (PDCa) activity
in patients with intermittent claudication (IC; open symbols) and
control subjects (closed symbols).vidual’s Cv for performance,
10 then most patients responded
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was inversely related to baseline walking performance, which
demonstrates that poorer performers experienced the greatest
benefit from carbohydrate supplementation. A similar effect
has been observed for the “metabolic enhancer” propionyl-L-
carnitine, which is thought to also act primarily on carbohy-
drate or intermediary metabolism.3,10 These preliminary data
raise the possibility that metabolic factors intrinsic to skeletal
muscle, which are altered by carbohydrate or propionyl-L-
carnitine supplementation, may limit walking performance in
a subgroup of patients with claudication, that is, poorer per-
formers.
Although the locus of any metabolic limitation within
skeletal muscle is not clear, recent studies in our laboratory
have focused on the mitochondrial oxidation of carbohy-
drate. In mitochondria isolated from the gastrocnemius
muscles of patients with claudication the PDC-dependent
oxidation of carbohydrate was positively related to walking
performance, and was higher in the exercise-trained state.8
In a separate study PDCa activity was 25% lower (P  .05)
in patients with claudication compared with healthy control
subjects.9 These same patients comprised the intermittent
claudication group in the present study, and patients with a
relatively low baseline measure of PDCa activity experi-
enced the greatest performance benefit from carbohydrate
supplementation (Fig 4). These data suggest that variation
in muscle PDCa activity may be linked to the performance
benefit of carbohydrate supplementation in intermittent
claudication.
It is not clear how relieving a metabolic limitation
improves walking performance in intermittent claudica-
tion, particularly given that hemodynamic limitations are
thought to predominate.1 In animal or human models of
limb ischemia complete activation of PDC in resting isch-
emic skeletal muscle reduces phosphocreatine hydrolysis,
Fig 5. Relationship between relative change in walking perfor-
mance with carbohydrate supplementation from baseline, and
corresponding change in body weight in patients with intermittent
claudication (IC; open symbols) and control subjects (closed sym-
bols).lactate accumulation, and fatigue during subsequent exer-cise sustained for several minutes.13,14 These metabolic
effects are thought to reflect acceleration of the VO2 re-
sponse to exercise secondary to increased substrate provi-
sion (ie, glucose-derived acetyl coenzyme A) for mitochon-
drial respiration.15 Compared with control subjects, the
kinetic response of VO2 to flat-level walking is twice as slow
in the present group of patients with claudication, and low
PDCa activity before exercise may contribute to this im-
paired response, given our previous observation of a nega-
tive correlation (r  0.56) between the VO2 time con-
stant and PDCa activity in intermittent claudication.9
Consequently, increasing PDCa through carbohydrate
supplementation could increase the kinetic response of
VO2, and in the present study this is supported by the
significant correlation between PDCa activity and the effect
of carbohydrate supplementation on the VO2time con-
stant. Inasmuch as the VO2 time constant is correlated with
walking performance in intermittent claudication,9 these
data raise the hypothesis that carbohydrate supplementa-
tion increases walking performance by at least in part alter-
ing the kinetic response of VO2.
An increase in muscle or liver glycogen through carbo-
hydrate supplementation is associated with an increase in
tissue water content, both of which would explain the
increase in body weight in patients and control subjects. An
increase in body weight will affect walking performance
more when the body is moved through a vertical distance,
as when walking up a gradient. In the present study the
treadmill gradient was increased incrementally after sub-
jects had walked on a flat level for 5 minutes; thus the
negative effects of weight gain on performance would be
experienced most by those who walked beyond this point
and who proceeded to higher gradients. This helps to
explain howwalking performance was reduced under CHO
in control subjects (Fig 5), whereas vertical work, which
accounts for changes in body weight, was not significantly
altered. In addition, larger weight gain was associated with
a larger reduction in performance in control subjects only
(Fig 5). That this relationship was not observed in patients
with claudication was probably due to the relatively limited
vertical work they performed and the variable ergogenic
effects caused by metabolic improvements. Consequently
the magnitude of the performance response to carbohy-
drate supplementation in intermittent claudication proba-
bly depends somewhat on the extent of the weight gain and
the proportion of the test that was spent translating the
body in the vertical direction.
A major limitation of the present study is its relatively
small sample size. In this context it can be argued that the
significant correlations we observed among the patients
with claudication are simply due to the influence of a few
large responders. However, the significant correlations that
relate to the positive effect of carbohydrate supplementa-
tion in the patients were not affected by removal of the
largest responders (see Results), which suggests that these
relationships are robust.Moreover, these relationships were
consistently different from those observed in the control
subjects, which suggests that the effect of the supplement
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claudication. Finally, this is a physiologic study, not a large
clinical investigation. Thus it provides new data that can
form the basis of clinical investigations of dietary carbohy-
drate involving much larger groups of patients with inter-
mittent claudication.
In conclusion, preliminary data show that carbohydrate
supplementation significantly improves walking perfor-
mance in patients with intermittent claudication compared
with healthy control subjects and that a relatively greater
benefit is observed in patients more severely affected. That
this occurred in the presence of increased carbohydrate
oxidation and was inversely related to muscle PDCa activity
supports the hypothesis that low rates of muscle carbohy-
drate oxidation may contribute to exercise intolerance in
peripheral arterial disease. Although the overall effect of
carbohydrate supplementation was small, that this effect
occurred in response to a short period of supplementation
and varied considerably among patients suggests that fur-
ther study of carbohydrate supplementation is warranted.
We thank Connie Wishart and Anita Green for their
technical assistance.
REFERENCES
1. Green S. Haemodynamic limitations and exercise performance in pe-
ripheral arterial disease. Clin Physiol 2002;22:81-91.
2. Sorlie D, Myhre K. Lower leg blood flow in intermittent claudication.
Scand J Clin Lab Invest Suppl 1978;38:171-9.
3. Brevetti G, di Lisa F, Perna S,Menabo R, Barbato R,Martone VD, et al.
Carnitine-related alterations in patients with intermittent claudication.
Circulation 1996;93:1685-9.4. Brass EP, Hiatt WR. Acquired skeletal muscle metabolic myopathy in
atherosclerotic peripheral arterial disease. Vasc Med 2000;5:55-9.
5. Dahllof A-G, Holm J, Kral J, Schersten T. The relationship between
glycogen content of leg muscles and working capacity in patients with
intermittent claudication. Acta Chir Scand 1975;141:329-32.
6. Peters SJ, St Amand TA, Howlett RA, Heigenhauser GJF, Spriet LL.
Human skeletal muscle pyruvate dehydrogenase kinase activity increases
after a low-carbohydrate diet. Am J Physiol 1998;275:E980-6.
7. Putman C, Spriet L, Hultman E, Lindinger M, Lands L, McKelvie R, et
al. Pyruvate dehydrogenase activity and acetyl group accumulation
during exercise after different diets. Am J Physiol 1993;265:E752-60.
8. Hou X-Y, Green S, Askew C, Barker G, Green A, Walker PW. Skeletal
muscle mitochondrial ATP production rate and walking performance in
peripheral arterial disease. Clin Physiol Funct Imaging 2002;22:81-91.
9. Barker G, Green S, Green A, Walker PM. Walking performance, VO2
kinetics and resting skeletal muscle pyruvate dehydrogenase complex
activity in peripheral arterial disease. Clin Sci 2004;106:241-9.
10. Barker G, Green S, Askew C, Green A, Walker P. Effect of propionyl-
L-carnitine on exercise performance in peripheral arterial disease. Med
Sci Sports Exerc 2001;33:1415-22.
11. Peronnet F, Massicotte D. Table of nonprotein respiratory quotient: an
update. Can J Sport Sci 1991;16:23-9.
12. Constantin-Teodosiu D, Cederblad G, Hultman E. A sensitive assay of
pyruvate dehydrogenase complex in human muscle tissue. Anal Bio-
chem 1991;198:347-51.
13. Timmons J, Poucher S, Constantin-Teodosiu D,Worrall V,Macdonald
I, Greenhaff P. Metabolic response of canine gracilis muscle during
contraction with partial ischemia. Am J Physiol 1996;270:E400-6.
14. Timmons J, Gustafsson T, Sundberg E, Jansson E, Greenhaff P. Sub-
strate availability limits human skeletal muscle oxidative ATP regener-
ation at the onset of ischemic exercise. J Clin Invest 1998;101:79-85.
15. Howlett RA, Heigenhauser GJF, Hultman E, Hollidge-Horvat MG,
Spriet LL. Effects of dichloroacetate infusion on human skeletal muscle
metabolism at the onset of exercise. Am J Physiol 1999;277:E18-25.Submitted May 25, 2004; accepted Jul 4, 2004.
